S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:GBT

Global Blood Therapeutics Stock Forecast, Price & News

$49.92
+0.15 (+0.30 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$49.10
Now: $49.92
$50.68
50-Day Range
$40.57
MA: $44.62
$49.77
52-Week Range
$36.49
Now: $49.92
$87.54
Volume1.35 million shs
Average Volume860,916 shs
Market Capitalization$3.09 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.39
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Global Blood Therapeutics logo

MarketRank

Overall MarketRank

1.60 out of 5 stars

Medical Sector

251st out of 1,558 stocks

Pharmaceutical Preparations Industry

130th out of 638 stocks

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700
Employees352

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.11 million
Book Value$9.61 per share

Profitability

Net Income$-266,770,000.00
Net Margins-332.94%

Miscellaneous

Market Cap$3.09 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$49.92
+0.15 (+0.30 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

How has Global Blood Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GBT stock has decreased by 9.0% and is now trading at $49.92.
View which stocks have been most impacted by COVID-19
.

Is Global Blood Therapeutics a buy right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Global Blood Therapeutics stock.
View analyst ratings for Global Blood Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Global Blood Therapeutics?

Wall Street analysts have given Global Blood Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Global Blood Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Global Blood Therapeutics
.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by $0.25. The business had revenue of $37 million for the quarter, compared to analysts' expectations of $44.56 million. Global Blood Therapeutics had a negative return on equity of 56.43% and a negative net margin of 332.94%. During the same quarter last year, the business posted ($1.07) EPS.
View Global Blood Therapeutics' earnings history
.

What price target have analysts set for GBT?

18 analysts have issued 12 month price targets for Global Blood Therapeutics' stock. Their forecasts range from $45.00 to $152.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $96.67 in the next year. This suggests a possible upside of 93.6% from the stock's current price.
View analysts' price targets for Global Blood Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Global Blood Therapeutics' key competitors?

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Square (SQ).

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:
  • Dr. Ted W. Love, Pres, CEO & Director (Age 62, Pay $1.14M)
  • Mr. Jeffrey S. Farrow, CFO & Principal Accounting Officer (Age 59, Pay $689.62k)
  • Dr. Brian Edwin Cathers, Chief Scientific Officer (Age 51, Pay $651.74k)
  • Mr. David L. Johnson, Chief Commercial Officer (Age 52, Pay $708.12k)
  • Dr. David R. Phillips, Founder & Advisor
  • Mr. Matthew P. Jacobson, Founder & Advisor
  • Dr. Andrej Sali, Founder & Advisor
  • Ms. Nazila Habibizad, Sr. VP of Operations
  • Stephanie Yao, Sr. Director of Corp. Communications & Investor Relations
  • Ms. Tricia Borga Suvari, Chief Legal Officer & Sec. (Age 60)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include First Midwest Bank Trust Division (0.23%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends for Global Blood Therapeutics
.

Which institutional investors are buying Global Blood Therapeutics stock?

GBT stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division.
View insider buying and selling activity for Global Blood Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $49.92.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $3.09 billion and generates $2.11 million in revenue each year. The company earns $-266,770,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Global Blood Therapeutics employs 352 workers across the globe.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is www.gbt.com.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.